These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 9112630

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
    Nagase H, Enjyoji K, Kamikubo Y, Kitazato KT, Kitazato K, Saito H, Kato H.
    Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
    [Abstract] [Full Text] [Related]

  • 7. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
    Cunningham AC, Hasty KA, Enghild JJ, Mast AE.
    Biochem J; 2002 Oct 15; 367(Pt 2):451-8. PubMed ID: 12117418
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
    Burgering MJ, Orbons LP, van der Doelen A, Mulders J, Theunissen HJ, Grootenhuis PD, Bode W, Huber R, Stubbs MT.
    J Mol Biol; 1997 Jun 13; 269(3):395-407. PubMed ID: 9199408
    [Abstract] [Full Text] [Related]

  • 11. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
    Iakhiaev A, Ruf W, Rao LV.
    Thromb Haemost; 2001 Mar 13; 85(3):458-63. PubMed ID: 11307815
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
    Peraramelli S, Suylen DP, Rosing J, Hackeng TM.
    Thromb Haemost; 2012 Aug 13; 108(2):266-76. PubMed ID: 22627666
    [Abstract] [Full Text] [Related]

  • 15. Heterogeneity of plasma tissue factor pathway inhibitor.
    Broze GJ, Lange GW, Duffin KL, MacPhail L.
    Blood Coagul Fibrinolysis; 1994 Aug 13; 5(4):551-9. PubMed ID: 7841311
    [Abstract] [Full Text] [Related]

  • 16. [Tissue factor pathway inhibitor (TFPI) and its role in pathology].
    Rucińska M, Gacko M, Skrzydlewski Z.
    Postepy Hig Med Dosw; 1997 Aug 13; 51(4):421-30. PubMed ID: 9446103
    [Abstract] [Full Text] [Related]

  • 17. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
    Liu Y, Stack SM, Lakka SS, Khan AJ, Woodley DT, Rao JS, Rao CN.
    Arch Biochem Biophys; 1999 Oct 01; 370(1):112-8. PubMed ID: 10496984
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
    Valentin S, Reutlingsperger CP, Nordfang O, Lindhout T.
    Thromb Haemost; 1995 Dec 01; 74(6):1478-85. PubMed ID: 8772224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.